These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 17846602)
1. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Kim JG; Sohn SK; Chae YS; Yang DH; Lee JJ; Kim HJ; Shin HJ; Jung JS; Kim WS; Kim DH; Suh C; Kim SJ; Eom HS; Bae SH Bone Marrow Transplant; 2007 Nov; 40(10):919-24. PubMed ID: 17846602 [TBL] [Abstract][Full Text] [Related]
2. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790 [TBL] [Abstract][Full Text] [Related]
3. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Escalón MP; Stefanovic A; Venkatraman A; Pereira D; Santos ES; Goodman M; Byrnes JJ; Fernandez HF Bone Marrow Transplant; 2009 Jul; 44(2):89-96. PubMed ID: 19169287 [TBL] [Abstract][Full Text] [Related]
4. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Yusuf RZ; Dey B; Yeap BY; McAfee S; Attar E; Sepe PS; Dube C; Spitzer TR; Ballen KK Bone Marrow Transplant; 2009 Jan; 43(1):37-42. PubMed ID: 18794868 [TBL] [Abstract][Full Text] [Related]
5. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305 [TBL] [Abstract][Full Text] [Related]
6. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. de Magalhaes-Silverman M; Lister J; Rybka W; Wilson J; Ball E Bone Marrow Transplant; 1997 Apr; 19(8):777-81. PubMed ID: 9134168 [TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091 [TBL] [Abstract][Full Text] [Related]
8. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Kröger N; Hoffknecht M; Hänel M; Krüger W; Zeller W; Stockschläder M; de Wit M; Weh HJ; Kabisch H; Erttmann R; Zander AR Bone Marrow Transplant; 1998 Jun; 21(12):1171-5. PubMed ID: 9674847 [TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Weaver CH; Schwartzberg L; Rhinehart S; West J; Zhen B; West WH; Buckner CD Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973 [TBL] [Abstract][Full Text] [Related]
10. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066 [TBL] [Abstract][Full Text] [Related]
11. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Copelan EA; Penza SL; Pohlman B; Avalos BR; Goormastic M; Andresen SW; Kalaycio M; Bechtel TP; Scholl MD; Elder PJ; Ezzone SA; O'Donnell LC; Tighe MB; Risley GL; Young DC; Bolwell BJ Bone Marrow Transplant; 2000 Jun; 25(12):1243-8. PubMed ID: 10871728 [TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Wadehra N; Farag S; Bolwell B; Elder P; Penza S; Kalaycio M; Avalos B; Pohlman B; Marcucci G; Sobecks R; Lin T; Andrèsen S; Copelan E Biol Blood Marrow Transplant; 2006 Dec; 12(12):1343-9. PubMed ID: 17162217 [TBL] [Abstract][Full Text] [Related]
13. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. Yoon DH; Lee DH; Choi DR; Sohn BS; Kim S; Kim SW; Lee JS; Lee SW; Huh J; Suh C Bone Marrow Transplant; 2011 Jan; 46(1):105-9. PubMed ID: 20383213 [TBL] [Abstract][Full Text] [Related]
14. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663 [TBL] [Abstract][Full Text] [Related]
15. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290 [TBL] [Abstract][Full Text] [Related]
16. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921 [TBL] [Abstract][Full Text] [Related]
17. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059 [TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas. Mabed M; Al-Kgodary T Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587 [TBL] [Abstract][Full Text] [Related]
19. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia. Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217 [TBL] [Abstract][Full Text] [Related]
20. BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. Talamo G; Claxton DF; Dougherty DW; Ehmann CW; Sivik J; Drabick JJ; Rybka W Bone Marrow Transplant; 2009 Aug; 44(3):157-61. PubMed ID: 19204716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]